Shots:
- Otsuka, via its subsidiary Otsuka America, has entered into an agreement to fully acquire Transcend, with an aim to expand its portfolio in psychiatric & neurological indications
- As per the deal, Otsuka will acquire Transcend for $700M upfront, & ~$525M in sales milestones, representing the total deal value of ~$1.225B; closing is expected in the Q2’26
- Acquisition will add TSND-201 (methylone) to Otsuka’s pipeline, advancing to P-III for PTSD with US patient recruitment underway, with Transcend developing novel prodrugs to enhance its efficacy, safety, & tolerability, with a candidate selected & nonclinical studies ongoing toward an FDA IND filing
Ref: Otsuka | Image: Transcend | Press Release
Related News: Otsuka Pharmaceutical Reports P-III (VISIONARY) Trial Data on Voyxact for IgA Nephropathy (IgAN)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
